Earnest Partners Llc increased Mueller Water (MWA) stake by 1.55% reported in 2017Q3 SEC filing. Earnest Partners Llc acquired 125,808 shares as Mueller Water (MWA)’s stock declined 10.59%. The Earnest Partners Llc holds 8.26 million shares with $105.76 million value, up from 8.14 million last quarter. Mueller Water now has $1.75 billion valuation. The stock decreased 3.17% or $0.36 during the last trading session, reaching $11. About 976,152 shares traded. Mueller Water Products, Inc. (NYSE:MWA) has risen 8.65% since March 1, 2017 and is uptrending. It has underperformed by 8.05% the S&P500.
Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report $-0.35 EPS on March, 7.They anticipate $0.07 EPS change or 25.00% from last quarter’s $-0.28 EPS. After having $0.37 EPS previously, Nektar Therapeutics’s analysts see -194.59% EPS growth. The stock decreased 3.88% or $3.49 during the last trading session, reaching $86.56. About 1.33M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since March 1, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.
Since September 6, 2017, it had 0 insider buys, and 18 sales for $25.90 million activity. Hora Maninder sold 7,583 shares worth $189,575. Another trade for 4,000 shares valued at $87,440 was made by KUEBLER CHRISTOPHER A on Friday, September 22. ROBIN HOWARD W also sold $2.02M worth of Nektar Therapeutics (NASDAQ:NKTR) on Monday, October 9. Shares for $404,664 were sold by Nicholson John on Friday, February 16. $2.93 million worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Labrucherie Gil M. $2.41M worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Gergel Ivan P. on Friday, September 29. $109,850 worth of stock was sold by Lingnau Lutz on Friday, September 22.
Investors sentiment decreased to 1.4 in Q3 2017. Its down 0.49, from 1.89 in 2017Q2. It worsened, as 15 investors sold Nektar Therapeutics shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Employees Retirement Systems Of Texas invested 0.03% in Nektar Therapeutics (NASDAQ:NKTR). Asset Management reported 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). 26,656 are owned by Stifel Corporation. 755 were reported by Hanson Mcclain. Vanguard Group stated it has 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Barclays Public Limited Com has 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR) for 231,932 shares. Invesco Limited has 0.03% invested in Nektar Therapeutics (NASDAQ:NKTR). Citadel Advisors Ltd Com owns 118,943 shares. Svcs Automobile Association stated it has 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Credit Suisse Ag holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 366,506 shares. Public Employees Retirement Association Of Colorado invested in 0.01% or 29,177 shares. Rothschild Asset Mngmt holds 0.31% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 1.18 million shares. Bridger owns 3.27% invested in Nektar Therapeutics (NASDAQ:NKTR) for 2.27 million shares. One Trading Ltd Partnership holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 26,032 shares. 5,603 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank).
Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $13.88 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.
Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. J.P. Morgan maintained the stock with “Buy” rating in Tuesday, July 18 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, August 9 by Roth Capital. The rating was downgraded by TheStreet to “Hold” on Wednesday, August 26. Canaccord Genuity initiated Nektar Therapeutics (NASDAQ:NKTR) rating on Thursday, November 9. Canaccord Genuity has “Buy” rating and $35.0 target. The rating was maintained by Roth Capital on Thursday, July 20 with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Tuesday, May 30 by Roth Capital. The stock has “Buy” rating by Aegis Capital on Tuesday, November 8. The firm earned “Buy” rating on Wednesday, August 16 by Jefferies. The firm has “Buy” rating given on Wednesday, November 8 by Jefferies. The firm has “Buy” rating given on Monday, June 5 by Aegis Capital.
Earnest Partners Llc decreased First Potomac Re (NYSE:FPO) stake by 2.24M shares to 211,716 valued at $2.36M in 2017Q3. It also reduced Itau Unibanc (NYSE:ITUB) stake by 85,704 shares and now owns 3.50M shares. Travelers Cos In (NYSE:TRV) was reduced too.
Investors sentiment increased to 1.42 in Q3 2017. Its up 0.50, from 0.92 in 2017Q2. It increased, as 14 investors sold MWA shares while 57 reduced holdings. 33 funds opened positions while 68 raised stakes. 132.25 million shares or 0.14% less from 132.44 million shares in 2017Q2 were reported. 12,000 are owned by Gabelli & Investment Advisers Incorporated. Principal Group reported 350,661 shares. Raymond James And Associates holds 0% or 123,663 shares in its portfolio. Victory Cap Management holds 0% or 20,625 shares. Susquehanna Interest Group Incorporated Llp invested in 0% or 141,342 shares. Geode Capital Mngmt Ltd invested 0.01% of its portfolio in Mueller Water Products, Inc. (NYSE:MWA). Parametrica Mgmt Ltd invested in 0.15% or 27,200 shares. Usca Ria Limited Com reported 0.03% of its portfolio in Mueller Water Products, Inc. (NYSE:MWA). Balyasny Asset Mngmt Llc owns 0% invested in Mueller Water Products, Inc. (NYSE:MWA) for 13,723 shares. United Kingdom-based Gsa Ptnrs Limited Liability Partnership has invested 0.02% in Mueller Water Products, Inc. (NYSE:MWA). Frontfour Group Ltd owns 560,846 shares. Glenmede Tru Na reported 316 shares. Moreover, Hsbc Public Limited has 0% invested in Mueller Water Products, Inc. (NYSE:MWA) for 13,179 shares. Teton Advisors has 75,900 shares. Citigroup owns 4,720 shares for 0% of their portfolio.
Among 11 analysts covering Mueller Water Products (NYSE:MWA), 8 have Buy rating, 1 Sell and 2 Hold. Therefore 73% are positive. Mueller Water Products had 30 analyst reports since January 12, 2016 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, September 5 by Boenning \u0026 Scattergood. The firm has “Buy” rating by Nomura given on Friday, February 2. The stock has “Outperform” rating by RBC Capital Markets on Thursday, April 28. The firm has “Market Perform” rating given on Wednesday, March 15 by Cowen & Co. On Thursday, April 28 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Outperform” rating given on Friday, March 24 by Oppenheimer. Cowen & Co maintained Mueller Water Products, Inc. (NYSE:MWA) on Wednesday, September 20 with “Hold” rating. IBC maintained the shares of MWA in report on Thursday, May 11 with “Buy” rating. The stock has “Hold” rating by Robert W. Baird on Friday, November 10. The rating was maintained by RBC Capital Markets on Wednesday, July 5 with “Buy”.
The post Analysts See $-0.35 EPS for Nektar Therapeutics (NKTR); Earnest Partners Has Raised By $1.51 Million Its Mueller Water (MWA) Stake appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/01/analysts-see-0-35-eps-for-nektar-therapeutics-nktr-earnest-partners-has-raised-by-1-51-million-its-mueller-water-mwa-stake/
No comments:
Post a Comment